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Abstract 
Glioblastoma multiform (GBM) is one of the most lethal forms of brain cancers. The biggest difficulties for 
diagnostics and treatment of GBM underlie in its dynamic and complex macro and microenvironment. Glioma 
cells, stromal cells and tumor-associated immune cells (microglia/macrophage-TAMs) become a complex tissue 
with physical and chemical communication network. TAMs are the predominant infiltrating immune cells in 
malignant GBMs and stimulate tumor invasion, angiogenesis, and metastasis. The epidermal growth factor (EGF) 
and colony stimulating factor 1 (CSF-1) paracrine signaling loop plays a key role in communication between 
glioma cells and TAMs. We developed a mathematical model to investigate macrophage-glioma cell interactions 
using CSF-1 and EGF paracrine-acting agents. Our model presents change of EGF and CSF-1 concentration both 
on the surfaces of cells and within a well-defined tumor microenvironment, in a domain, with respect to interaction 
time and distance between TAMs and glioma cells. Our simulation results confirm that from low-grade glioma to 
high-grade glioma, concentration of CSF-1 increases both on the surfaces of macrophages and within the domain. 
Therefore, reproduction and adsorption of CSF-1 correlates with the grade of malignancy in human gliomas, which 
is a good agreement with recent findings.  
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1. Introduction  
Glioblastoma multiform (GBM) is one of the most lethal forms of brain cancer in humans. Survival of 
patients could be extended up to 15 months with chemotherapy, radiation and surgery1-4 yet, multiple 
challenge remains for better clinical outcomes5, 6. The biggest difficulties for diagnostic and treatment of 
GBM underlie in its complex macro and microenvironment. The macro environment of brain presents 
several complexities such as composing of several sensitive cell types to chemotherapeutic reagents; being 
surrounded by blood-brain barrier that limits delivery of drugs, and the skull that restricts growth of 
tumors. On the other hand, microenvironment of GBM is also highly complex, dynamic hierarchical cell 
society due to presence of diverse cell types with distinct phenotypes and different proliferative potentials. 
GBM cells co-evolve with stromal and tumor-associated immune cells (microglia/macrophage) and form 
complex physical and chemical cell-cell communication network. TAMs are abundant and the 
predominant infiltrating immune cells in malignant GBMs, which are present at World Health 
Organization (WHO) grade II-IV gliomas7-10. During tumor progression, macrophages can stimulate tumor 
invasion, angiogenesis, and metastasis11. Although the role of infiltrated macrophages in tumor progression 
has been recognized, still the precise nature of the interaction mechanisms between tumor cells and 
macrophages has not been elucidated12. Mills et al. extended an in vivo model for the function of TAMs 
and suggested two states of TAMs as activated (M1) and alternatively activated (M2) macrophages. M1 
and M2 TAMs differ in activating signals, expression of receptors, cytokine production and biological 
behavior. This suggestion describes that TAMs with M1 polarization are foes and TAMs with M2 
polarization are friends for tumors7, 13. Tumor-derived molecules, such as colony-stimulating factor 1 
(CSF-1), can polarize glioma-infiltrating macrophages towards M2 polarization and result in production of 
anti-inflammatory molecules14-16 and epidermal growth factor (EGF), which acts in return on EGF receptor 
(EGFR) on the carcinoma cells to promote invasion17. EGF-CSF-1 signaling affects the ratio of cell types 
in aggregates and enables glioma cells to infiltrate into the brain parenchyma5. Since GBMs are highly 
complex with unpredictable patterns, several mathematical models have been used to reveal its complexity 
and predict its progress18, 19. Particularly, compared to other scientific boards, neuro-oncology still requires 
more effort to propose predictive tools that could accurately simulate the behavior of malignant gliomas20, 
21. Martirosyan and his coworkers summarized the mathematical models that describe different aspects of 
GBM growth and evaluation such as spheroid models, metabolic and vascular models, morphological 
models, and treatment models20.  
 
Among them, spheroid models represent a powerful theoretical framework to study initial growth of GBM 
when proliferation and diffusion of glioblastoma cells are the major players in the tumor initiation. These 
types of models composed of reaction-diffusion models, simple discrete models and continuum models. 
Stein et al. used bright field image sequences to estimate number of cells in the tumor spheroids and 
described a continuum mathematical model to quantitatively interpret the data. After fitting quantitative 
and experimental data, they observed that glioma cells with EGF receptor show less cell-cell adhesion and 
invade in a more biased manner and greater rate22.  Banerjee et al. developed a mathematical model 
considering the interactive dynamics of glioma cells, macrophages, cytotoxic T-lymphocytes and T11 
Target structure (T11TS), which is a membrane glycoprotein and affects the functional state of immune 
cells. Their model concluded that T11T structure might be used as a drug target for effective treatment of 
brain tumors6. Aubert and Bandoual proposed a two dimensional model that quantified the strength of cell-
cell adhesion using a probability threshold. The agreement of mathematical modeling with experimental 
results approved that cell-cell adhesion is extremely important for the growth and behavior of glioma 
cells23, 24. Considering biased diffusion in glioblastoma, Fort and Sole’s improved standard reaction-
diffusion-advection model pointed that glioma cells move in a bias towards the invasion front instead of 
moving equally in all directions. It provides a great agreement with experiments25.  
 
The vascular and metabolic models are related to invasiveness and aggressiveness of the tumor that 
requires more nutrient supply consequently; these models oftentimes predict the onset of angiogenesis and 
creation of vasculature20. In this concept, some models analysed collective cell migration, tumor cell 
spatial distribution, morphology and viability using conservation laws26-28. Some models were 
compartmentalized via dividing tumor cell populations into normal, hypoxic, and necrotic cell groups to 
cover all dynamics of tumor microenvironment19, 29-31. Some models investigated the phenotypic switch that 
occurs from proliferative state to invasive state in glioma cells as function of hypoxia32. The morphological 
models uses discrete models and reaction-diffusion models to investigate the microscopic and macroscopic 
morphological changes, glioma growth, invasion based on cell-cell and cell-extracellular matrix adhesion, 
hypoxia, chemotaxis, homotype attractions, substrate gradients (glucose, oxygen) and other 
microenvironmental parameters33-36. In the treatment models the ultimate goal is providing solutions for 
better treatment outcome, prolonging and improving patient life. As mentioned, treatment of glioblastoma 
is not very efficient compared to other cancer types and better strategies are urgently needed. The 
modeling strategies target better treatment regimen using radiotherapy, chemotherapy, patient MRI data 
and resection in conjunction with two-, three- and four-dimensional computer modeling systems37. Thus, 
chemotherapy and radiotherapy is able to simulated with different drugs38 and dose schedules, partial 
resection of tumor and filling the ablated volume with different chemicals such as cerebrospinal fluid, 
chemoattractants39. 
 
Despite efforts to understand the dynamics of glioma cells and macrophage interactions, little data is 
available to suggest the partnership between glioma cells and M2 type TAMs. However, most of the 
findings are based on human end-stage tumor samples obtained from surgical secretions. In order to reveal 
the nature of interaction between glioma cells and macrophages, efforts may focus on studying the nature 
of interaction between glioma cells and macrophages arises at tumor onset8. Based on the need for better 
understanding of the macrophage-tumor cell interactions in tumor microenvironment, mathematical 
models, which reveal and simulate the nature of these interactions, are of high challenge and consideration. 
In this work, we present a computational model for further investigation of macrophage-glioma cell 
interactions focusing on concentration change of paracrine-acting agents (CSF-1 and EGF) in a defined 
microenvironment (domain) and on the cellular surfaces. 
2. Model 
Recent clinical experiments reported that TAMs facilitate invasiveness of GBM through EGF-CSF-1 paracrine 
signaling loop17. Macrophages secrete EGF and respond to CSF-1; similarly glioma tumor cells express CSF-1 and 
respond to EGF via chemotaxis, Figure 1. This cooperation enables glioma cells to coordinate their aggregation 
and migration via macrophage-facilitated dissemination from primary tumor to surrounding healthy brain tissue 5, 16, 
17. To reveal the interaction mechanism between glioma cells and macrophages, we developed a computational 
model and simulate the EGF and CSF-1 paracrine loop both on the cell surfaces and in a domain consist of 
macrophages and glioma tumor cells. Figure 1a illustrates EGF and CSF-1 interaction loop at single cell level 
while the schematic in Figure 1b demonstrates EGF and CSF-1 interaction in a domain at population level. 
 Figure 1: Schematics for the EGF-CSF1 signaling loop. a) Macrophage and glioma cell interact 
through EGF-CSF-1 signaling loop. Glioma cells secrete CSF-1 and it binds to macrophages and makes 
them express EGF, which acts on CSF-1 secretion of glioma tumor cells. b) Schematic of 2D simulation 
domain to use reaction-diffusion models. Active surface for glioma cells represents the community of 
glioma cells and active surface for macrophages describes the community of macrophages present in the 
modeling domain. As a case study, it is assumed that these two communities have size of 25 µm as length 
of active surfaces and are in the distance of 5 μm from each other.  
 
In our modeling, we numerically solve the equations that govern the movement and binding of CSF-1 and 
EGF. Fick’s second law explains diffusive transport, where D is the diffusion coefficient. C is the 
concentration of species, ∆ is Laplacian and t is time. 
∂C/∂t=DΔC                                                                                                                                                    (1) 
 
Incorporating reaction-diffusion modeling, the nature of interaction in the paracrine signaling loop is described as 
follows40: 
𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝐷! ← 𝐶𝑆𝐹 − 1! + 𝐶𝑆𝐹 − 1𝑅 !!"!! 𝐶𝑆𝐹 − 1! !!"# !!  𝐷𝑃𝐶                                                               (2) 𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛(𝐷!) ← 𝐸𝐺𝐹! + 𝐸𝐺𝐹𝑅 !!"!! 𝐸𝐺𝐹! !!"#!!  𝐷𝑃𝐸                                                                              (3) 
 
CSF-1R represents the concentration of receptors on macrophage cell surface for binding of CSF-1 
secreted by glioma cells and EGFR represents the concentration of receptors located on glioma cell surface 
for binding of EGF secreted by macrophages. Kon-C and Kon-E incorporate the rate constants for CSF-1R and 
EGFR binding, respectively. Moreover, CSF-1s and EGFs are surface species and represent the 
concentration of bound CSF-1 on the macrophage and bound EGF on the glioma cell surfaces. Kdeg-C and 
Kdeg-E are the rate constants for degradation of CSF-1s and EGFs. DPC and DPE are the degradation of 
products. The CSF-1d and EGFd are bulk species in the domain and introduced at the rate of ϑC and ϑE at 
specific locations and have effective diffusion coefficient of DC and DE, respectively. In our calculations, 
including surface reaction and bulk diffusion expressions (2) and (3) are described with the following 
equations 40: 
 
∂CSF-1d/∂t=DC.ΔCSF-1d+ ϑC                                                                                                                        (4) 
∂CSF-1s/∂t=Kon-C.CSF-1d.(1 - CSF-1s) -Kdeg-C.CSF-1s                                                                                   (5) 
∂EGFd/∂t=DE.ΔEGFd+ϑE                                                                                                                                (6) 
∂EGFS/∂t= Kon-E.EGFd.(1 - EGFs) - Kdeg-E.EGFs                                                                                             (7)                                                                                 
 
Equations (4) and (6) are surface-reaction expressions and include the concentrations of free species (CSF-
1d and EGFd) and should be solved in combination with the mass balance of species in the domain. The 
coupling between bulk and surface expressions is obtained as boundary condition in the bulk’s mass 
expressions (equations (4) and (6)), which sets the flux of CSF-1d and EGFd at the active surfaces.  
Our mathematical model is based on the following assumptions: 
• The physical and chemical properties of domain and surface CSF-1 and EGF reagents are uniform 
and continuous. 
• The mass balance of the domain has been coupled to the mass balances of CSF-1 and EGF present 
on the active surfaces.  
• The initial condition concentrations of CSF-1 and EGF are zero.  
For the domain species, the boundary conditions at active surfaces couple the rate of the reactions at the 
surfaces with the concentration of free species in the domain: 
(-DC.∇CSF-1d) = -Kon-C. CSF-1d.(1 - CSF-1s)                                                                                                (8) 
(-DE.∇EGFd) = -Kon-E. EGFd.(1 - EGFs)                                                                                                         (9) 
 
In order to couple the reaction-diffusion expressions of CSF-1 and EGF, we have assumed that Kon-E varies 
based on the concentration of macrophages and glioma cells in the domain and a linear correlation occurs 
between ϑC, ϑE, Kon-C and Kon-E as follows, 
ϑC/ϑE = Kon-C / Kon-E                                                                                                                                       (10) 
 
Therefore, the value of Kon-E  for each glioma grade could be determined from equation (10). Definitions, 
default values and their references are provided in Table 1. 
 
The mathematical modeling deals with a diffusion occurring in a 2D domain, which is coupled, to a 
surface reaction phenomenon occur on a part of the domain’s boundary. The phenomenon in the domain 
refers to introduction of CSF-1d from the glioma and EGFd from the macrophages as sources and the 
surface phenomenon describes the binding of species from the domain to the active surfaces that reactions 
take place. 
Parameter Symbol Value Units References 
Diffusion of 𝑪𝑺𝑭𝟏𝒇 DC 1.6×10!!" m2/s 41 
Diffusion of 𝑬𝑮𝑭𝒇 DE 1.6×10!!" m2/s 41 
Degradation of 𝑪𝑺𝑭𝟏𝒃  Kdeg-C 1.9×10!! 1/s 42 
Degradation of 𝑬𝑮𝑭𝒃  Kdeg-E 1.9×10!! 1/s 42 
Secretion rate of 𝑪𝑺𝑭𝟏𝒇 ϑC / N_g 1.7×10!!" mol/m3.s 43 
Secretion rate of 𝑬𝑮𝑭𝒇 ϑE / N_g 1.7×10!!" mol/m3.s 44 
Binding rate of 𝑪𝑺𝑭𝟏𝒇 Kon-C 7.7×10! mol/m3.s 45 
 
Table 1: Table of parameters, their values and references used in simulation. 
 
Equations (4) and (6) are modeled using Transport of Diluted Species interface and equations (5 and 7) are 
described with General Form Boundary PDE interface in COMSOL Multiphysics 5. The equations of two 
interfaces are coupled considering expressions (8) and (9) as boundary conditions. 
The concentration of species in the domain and on the surfaces of the cells has been affected from the 
interaction of macrophages and glioma cells that are present in the domain. In this study, WHO grade I-IV 
gliomas are considered based on the concentration of glioma and macrophages. Table 2 describes number 
of macrophages and glioma cells at each grade of glioma brain cancer46. We calculated the value of Kon-E 
using equation (12) and using the number of macrophages and glioma cells in Table 247. 
WHO grades Macrophage (𝑵_𝒎) Glioma (𝑵_𝒈)  𝑲𝒐𝒏!𝑬 
I 2×10! 16×10! 6.1×10! 
II 1×10! 56×10! 4.3×10! 
III 2×10! 16×10! 2.5×10! 
IV 1×10! 26×10! 2×10! 
 




In this work, we have developed a continuum mathematical model that simulates the concentrations of 
EGF and CSF-1 paracrine reagents for the surface-bounded species on the active surfaces of macrophages, 
CSF-1s (mol/m2) and on the active surfaces of glioma tumor cells, EGFs (mol/m2), the secreted CSF-1d 
(mol/m3) and EGFd (mol/m3) as bulk concentrations (free reagents) in the domain. The simulations were 
performed for 24 hours. Figure 2 shows the schematic view and the change of CSF-1d after 24 hours of 
interaction between macrophages and glioma tumor cells in the domain for all WHO grades of gliomas (I 
(a), II (b), III (c) and IV (d)). According to modeling results, all color tables of Figure 2 are assigned to 
have 1.76×10!!" as minimum (blue) and 3.45×10!!" (red) as maximum reference values for CSF-1d.  
 
Likewise, Figure 3 shows the concentration gradient of EGFd after 24 hours interaction among 
macrophages and glioma tumor cells in the domain. The reference minimum value of EGFd is 4.25×10!!" 
(blue) and the reference maximum value is 2.67×10!!" (red) for the color table. The schematic images 
represent that the ratio for number of glioma cells to number of macrophages. Grade I glioma is close to 1, 
this ratio increases from grade I to grade IV, and reaches 260 at grade IV glioma.  
 
Figure 2: Concentrations of CSF-1d within the domain after 24 hours of macrophage-glioma cell 
interaction. The schematic images symbolize the WHO grades of the glioma including 2D-color table, which 
represents the concentration gradient of CSF-1d, and one-dimensional plot presents the change in the 
concentration of CSF-1d in x-direction of the domain. a) The grade I glioma with 2x107 macrophages and 
16x106 gliomas, b) the grade II glioma with 1x107 macrophages and 56x106 glioma cells, c) the grade III 
glioma with 2x106 macrophages and 16x107 glioma cells, and d) the grade IV glioma with 1x106 macrophages 
and 26x107 glioma cells.  For all grades of glioma, the initial concentration value of CSF-1d was set to zero. 
The simulation time was 24 hours. All color tables are assigned to have minimum (blue) and maximum (red) 
reference values of 1.76x10-26 and 3.45x10-16, respectively. Glioma cells and macrophages are located on 
their specific active surfaces and the number of cells in each image illustrates, in a symbolic way, the 
difference between the number of glioma cells and macrophages. The x-axis stands for the distance between 
macrophages and glioma cells; the origin is located at the active surface of glioma cells. 
 
  																		
Figure 3: Concentrations of EGFd within the domain after 24 hours of macrophage-glioma cell 
interaction. The schematic images symbolize the WHO grades of the glioma including 2D-color table, 
which represents the concentration gradient of EGFd, and one-dimensional plot presents the change in the 
concentration of EGFd in x-direction of the domain. a) The grade I glioma with 2x107 macrophages and 
16x106 glioma cells, b) the grade II glioma with 1x107 macrophages and 56x106 glioma cells, c) the grade 
III glioma with 2x106 macrophages and 16x107 glioma cells, and d) the grade IV glioma with 1x106 
macrophages and 26x107 glioma cells.  For all grades of glioma, the initial concentration value of EGFd 
was set to zero. The simulation time was 24 hours. All color tables are assigned to have minimum (blue) 
and maximum (red) reference values of 4.25x10-30 and 2.67x10-17, respectively. Glioma cells and 
macrophages are located on their specific active surfaces and the number of cells in each image illustrates, 
in a symbolic way, the difference between the number of glioma cells and macrophages. The x-axis stands 
for the distance between macrophages and glioma cells; the origin is located at the active surface of 
glioma cells. 
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One-dimensional plots in Figure 2 and Figure 3 illustrate the change in the concentration of CSF-1d and 
EGFd in x-direction of the domain for each stage. The x-axis represents the average displacement between 
the population of glioma cells and macrophages; it starts from the active surface of glioma cells (x = 0μm) 
and ends at the active surface of macrophages (x = 5μm). Consequently, the concentration of CSF-1d  




Figure 4: Time-dependent concentration changes for CSF-1s and CSF-1d for low-grade to high-
grade gliomas. a) Concentration of CSF-1s with respect to time from low-grade glioma to high-grade 
glioma. b) Concentration of CSF-1d with respect to time from low-grade glioma to high-grade glioma. 
The initial concentration values of CSF-1s and CSF-1d were zero. The simulations were performed for 
24 hours. The grade I glioma has 2x107 macrophages and 16x106 glioma cells, the grade II glioma has 
1x107 macrophages and 56x106 glioma cells, the grade III glioma has 2x106 macrophages and 16x107 





Figure 5: Time-dependent concentration changes for EGFs and EGFd for low-grade to high-grade 
gliomas. a) Concentration of EGFs with respect to time from low-grade glioma to high-grade glioma. b) 
Concentration of EGFd with respect to time from low-grade glioma to high-grade glioma. The initial 
concentration values of EGFs and EGFd were zero. The simulations were performed for 24 hours. The 
grade I glioma has 2x107 macrophages and 16x106 glioma cells, the grade II glioma has 1x107 
macrophages and 56x106 glioma cells, the grade III glioma has 2x106 macrophages and 16x107 glioma 
cells, and the grade IV glioma has 1x106 macrophages and 26x107 glioma cells. 
 
When the concentrations of adsorbed species on the cellular surface increase with time, the 
concentrations of domain species (CSF-1d and EGFd) decrease due to adsorption by active surfaces and 
coupling of reaction and diffusion phenomena at all glioma grades. For the grade I glioma, the number 
of macrophages was 1.25 times higher than the number of glioma cells in the domain. At grade II 
gliomas, macrophages are 0.17 times of glioma cells in the domain and the concentration of CSF-1s and 
CSF-1d was approximately 5.5 times of the concentration of EGFs and EGFd. For grade III and IV 
gliomas the ratio of macrophages to glioma cells are 0.01 and 0.003 and the ratio of CSF-1 species to 
EGF species are approximately 32 and 260, respectively. From grade I to grade IV gliomas, the ratio of 
macrophages to glioma cells approximately uniformly decreased, but based on the observations from 
the modeling this approximate uniformity could not be generalized to the ratio of domain species to 
surface species at each grade of glioma.  
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Figure 4 shows that for both species of CSF-1, grade I glioma has minimum concentration and towards 
high-grade glioma, which means increasing in the ratio of glioma cells to macrophages, CSF-1 bulk and 
surface species experience higher concentrations. Despite the CSF-1 species, Figure 5 illustrates that 
EGF species have the minimum concentrations for grade IV gliomas where the ratio of macrophages to 
glioma cells is the minimum.     
 
4. Conclusions 
We have presented a simple 2D co-culture model that investigates CSF-1 and EGF interaction in vitro 
from grades I to IV human glioma disease. Our model represents the difference in the surface-bounded 
(CSF-1s-EGFs) and bulk expressed (CSF-1d-EGFd) paracrine-signaling reagents of CSF-1 and EGF both 
at spatial and temporal resolution. Although most of the current models focus on measuring the total 
concentration of signalling molecules in a defined domain, our  model and prediction of the surface-
bounded concentration of signaling reagents provide a great potential to improve our understanding for 
mechanism of interaction between glioma cells and tumor-associated immune cells in the concept of 
tumor invasiveness and grade of the disease. The importance of bulk and surface-bounded cytokine 
classification, particularly in the concept of CSF-1 expression in glioblastoma multiform, was reported 
in Graf’s experimental paper in 199950. Their conclusion was membrane-bound cytokines were more 
potent than its soluble counterparts.  
 
Moreover, in our mathematical modeling, we observed that increasing the WHO grades of glioblastoma 
increases the concentration of CSF-1 both in the domain and on the surface of macrophages. However, 
the increase in the concentration of CSF-1 and decrease in the concentration of EGF do not obey the 
uniform change in the number of macrophages and glioma cells. In glioma microenvironment, 
macrophages depend upon CSF-1 for differentiation, migration and survival. Pyonteck et al., found that 
CSF-1R inhibition blocks glioma unexpected growth, progression and invasion 48. Therefore, CSF-1 is 
one of the main factors for macrophage and glioma survival in the glioblastoma multiform and its 
reproduction and adsorption needs to be increased from low to high-grade gliomas. Our mathematical 
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modeling approves the high reproduction of CSF-1 at high-grade gliomas as repoteted by Coniglio and 
his colleagues. They observed that CSF-1 levels were elevated in higher grade gliomas and approved 
that glioblastoma invasion completely depended on CSF-1R signaling 5. Bender et al., proposed that in 
a genetic screen for oncogenes driving astrocytomas, CSF-1 was regulated in nearly 70% of 
spontaneous astrocytomas49. In our mathematical model, increasing grade number of the disease results 
in elevating not only the bulk species, but also surface species of CSF-1. Glioma cells express more 
CSF-1 in the bulk and macrophages being affected from this high supply, adsorb more CSF-1 on their 
surfaces until the time to reach the steady state.  
 
As our next goal, we are planning to incorporate the cellular information such as division time of cells 
in our model to correlate whether the levels of CSF-1 and EGF impact cellular behaviour and tumor 
growth such as invasiveness. It will potentially provide more insights for building disease prediction 
models.  
 
Last but not least, our model simply allows introducing different types of cytokines (more signalling 
pathways) and cell types (glioma stem cells, astrocytes, and microglia) of glioma microenvironment 
while providing possibilities of upgrading from 2D to 3D microenvironment, where complexity, 
dynamic cellular distribution of different cell types and heterogeneity of glioma microenvironment will 
be more realistically mimicked and the obtained results will be extensively contributed to the 
development of personalized treatment and drug test models for  human brain tumors. 
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Table and figure legends: 
Figure 1: Schematics for the EGF-CSF1 signaling loop. a) Macrophage and glioma 
cell interact through EGF-CSF1 signaling loop. Glioma cells secrete CSF1 and it 
binds to macrophages and makes them express EGF, which acts on CSF1 secretion of 
glioma tumor cells. b) Schematic of 2D simulation domain to use reaction-diffusion 
models. Active surface for glioma cells represents the community of glioma cells and 
active surface for macrophages describes the community of macrophages present in 
the modeling domain. It is assumed that these two communities have size of 25 µm as 
length of active surfaces and are in the distance of 5 μm from each other.  
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Figure 2: Concentrations of CSF-1d within the domain after 24 hours of macrophage-
glioma cell interaction. The schematic images symbolize the WHO grades of the glioma 
including 2D-color table, which represents the concentration gradient of CSF-1d, and 
one-dimensional plot presents the change in the concentration of CSF-1d in x-direction of 
the domain. a) The grade I glioma with 2x107 macrophages and  16x106 gliomas, b) the 
grade II glioma with 1x107 macrophages and 56x106 glioma cells, c) the grade III glioma 
with 2x106 macrophages and 16x107 glioma cells, and d) the grade IV glioma with 1x106 
macrophages and 26x107 glioma cells.  For all grades of glioma, the initial 
concentration value of CSF-1d was set to zero. The simulation time was 24 hours. All 
color tables are assigned to have minimum (blue) and maximum (red) reference values of 
1.76x10-26 and 3.45x10-16, respectively. Glioma cells and macrophages are located on 
their specific active surfaces and the number of cells in each image illustrates in a 
symbolic way the difference between the number of glioma cells and macrophages. The 
x-axis stands for the distance between macrophages and glioma cells; the origin is 
located at the active surface of glioma cells. 
 
Figure 3: Concentrations of EGFd within the domain after 24 hours of macrophage-
glioma cell interaction. The schematic images symbolize the WHO grades of the 
glioma including 2D-color table, which represents the concentration gradient of EGFd, 
and one-dimensional plot presents the change in the concentration of EGFd in x-
direction of the domain. a) The grade I glioma with 2x107 macrophages and 16x106 
gliomas, b) the grade II glioma with 1x107 macrophages and 56x106 glioma cells, c) 
the grade III glioma with 2x106 macrophages and 16x107 glioma cells, and d) the 
grade IV glioma with 1x106 macrophages and 26x107 glioma cells.  For all grades of 
glioma, the initial concentration value of EGFd was set to zero. The simulation time 
was 24 hours. All color tables are assigned to have minimum (blue) and maximum 
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(red) reference values of 4.25x10-30 and 2.67x10-17, respectively. Glioma cells and 
macrophages are located on their specific active surfaces and the number of cells in 
each image illustrates in a symbolic way the difference between the number of glioma 
cells and macrophages. The x-axis stands for the distance between macrophages and 
glioma cells; the origin is located at the active surface of glioma cells. 
 
Figure 4: Time-dependent concentration changes for CSF-1s and CSF-1d for low-
grade to high-grade gliomas. a) Concentration of CSF-1s with respect to time from 
low-grade glioma to high-grade glioma. b) Concentration of CSF-1d with respect to 
time from low-grade glioma to high-grade glioma. The initial values of CSF-1s and 
CSF-1d concentration were zero and the simulations were performed for 24 hours. The 
grade I glioma has 2x107 macrophages and 16x106 gliomas, the grade II glioma has 
1x107 macrophages and 56x106 glioma cells, the grade III glioma has 2x106 
macrophages and 16x107 glioma cells, and the grade IV glioma has 1x106 
macrophages and 26x107 glioma cells. 
 
Figure 5: Time-dependent concentration changes for EGFs and EGFd for low-grade 
to high-grade gliomas. a) Concentration of EGFs with respect to time from low-grade 
glioma to high-grade glioma. b) Concentration of EGFd with respect to time from low-
grade glioma to high-grade glioma. The initial values of EGFs and EGFd 
concentration were zero and the simulations were performed for 24 hours. The grade I 
glioma has 2x107 macrophages and 16x106 gliomas, the grade II glioma has 1x107 
macrophages and 56x106 glioma cells, the grade III glioma has 2x106 macrophages 
and 16x107 glioma cells, and the grade IV glioma has 1x106 macrophages and 26x107 
glioma cells. 
Table 1: Table of parameters, their values and references used in simulation. 
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Table 2: The number of cells and the values of K On-E used in simulations were used 
from Lu and his co-workers study47. 
